AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 27,032 shares, an increase of 105.1% from the November 30th total of 13,177 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average daily trading volume, of 60,771 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 60,771 shares, the short-interest ratio is presently 0.4 days. Approximately 0.9% of the company’s stock are sold short.

AIM ImmunoTech Stock Performance

Shares of AIM ImmunoTech stock traded up $0.07 during midday trading on Monday, hitting $1.32. The company had a trading volume of 139,560 shares, compared to its average volume of 74,596. The company has a 50 day moving average of $1.67 and a 200 day moving average of $3.75. The stock has a market capitalization of $3.75 million, a P/E ratio of -0.06 and a beta of 1.19. AIM ImmunoTech has a 52-week low of $1.21 and a 52-week high of $36.00.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its earnings results on Monday, November 17th. The company reported ($1.57) EPS for the quarter. The firm had revenue of $0.03 million for the quarter. AIM ImmunoTech had a negative return on equity of 1,586.23% and a negative net margin of 14,062.50%. Equities research analysts forecast that AIM ImmunoTech will post -0.3 EPS for the current year.

Institutional Investors Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new position in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 0.37% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AIM. Zacks Research lowered AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Maxim Group upgraded AIM ImmunoTech to a “strong-buy” rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.